Wo JY, et al. - In this retrospective review of patients with borderline resectable or locally advanced pancreatic cancer, researchers assessed the tolerability and long term outcomes of dose-painted (DP) boost technique to regions of vessel involvement which preclude upfront surgical resection. They examined 99 such cases treated with DP-neoadjuvant chemoradiation from 2010 to 2015, with 50.4 Gy prescribed to tumor and regional lymph nodes and the region around the involved blood vessel was boosted to 58.8 Gy in 28 fractions. Findings demonstrated the feasibility as well as good tolerability of DP-neoadjuvant chemoradiation to regions of vessel involvement. Furthermore, as a result of treatment with neoadjuvant therapy including DP-chemoradiation, over one third of patients with initially deemed unresectable disease were able to undergo surgical resection.